readthroughSign in
Nov 13, 2026People

Adicet Bio director Andrew Sinclair resigns from board

Michael Grissinger takes over Sinclair's audit committee seat and becomes chair of the nominating and governance committee.

Adicet Bio, Inc. disclosed in a Form 8-K that Andrew Sinclair, Ph.D., a Class III member of the board of directors, notified the company on November 11, 2026 of his resignation from the board, the Audit Committee, and the Nominating and Corporate Governance Committee, effective November 13, 2026.1

The company said Dr. Sinclair's departure did not stem from any disagreement with management or the board, nor from any issue tied to the company's operations, policies, or practices.1 As a result of the resignation, the board will shrink from seven members to six.1

To fill the vacancy on the audit committee, the board, acting on the recommendation of the Nominating and Corporate Governance Committee, appointed current director Michael Grissinger to that committee on November 13, 2026.1 The board also concluded that Grissinger satisfies the independence requirements for audit committee members under Nasdaq listing standards and the Securities Exchange Act of 1934.1 Separately, Grissinger was named chairperson of the Nominating and Corporate Governance Committee.1

The filing was signed on November 13, 2026 by Nick Harvey, Adicet Bio's Chief Financial Officer.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.